Candel Therapeutics, Inc. (CADL)

Market Cap	173.44M
Revenue (ttm)	n/a
Net Income (ttm)	-37.94M
Shares Out	29.35M
EPS (ttm)	-1.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	447,573
Open	5.47
Previous Close	5.54
Day's Range	5.46 - 5.98
52-Week Range	0.66 - 11.40
Beta	0.92
Analysts	Strong Buy
Price Target	7.00 (+18.44%)
Earnings Date	May 9, 2024

About CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 27, 2021
• Employees: 42
• Stock Exchange: NASDAQ
• Ticker Symbol: CADL

Analyst Forecast

According to 2 analysts, the average rating for CADL stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 18.44% from the latest price.

Price Target

$7.0

(18.44% upside)

Analyst Consensus: Strong Buy